Chemotherapeutic and Biologic Agents as Radiosensitizers in Rectal Cancer

Seminars in Radiation Oncology

Volumn 13, Issue 4, 2003, Pages 454-468

  Zhu, Andrew X ^a   Willett, Christopher G ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN DERIVATIVE; CAPECITABINE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C9; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LEVAMISOLE; LOMUSTINE; METHYLCYCLOHEXYLCHLOROETHYLNITROSOUREA; OXALIPLATIN; RADIOSENSITIZING AGENT; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL DERIVATIVE;

ACNE; ANUS SPHINCTER; BLEEDING; BLOOD TOXICITY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DYSESTHESIA; EPISTAXIS; FATIGUE; FEVER; HAND AND FOOT SYNDROME; HEADACHE; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INFECTION; LIVER TOXICITY; LYMPH NODE METASTASIS; MALAISE; MOUTH ULCER; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OUTCOMES RESEARCH; PARESTHESIA; PERIPHERAL NEUROPATHY; PHLEBITIS; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEINURIA; RADIATION DERMATITIS; RASH; RECTUM CANCER; RECTUM RESECTION; REVIEW; STOMATITIS; SURVIVAL RATE; SYNDROME; THROMBOCYTOPENIA; THROMBOSIS; TUMOR VOLUME; VOMITING;

EID: 0242578674     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(03)00048-1     Document Type: Article

References (110)

1. Jemal A, Murray T, Samuels A: Cancer Statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Evans RM, Laskin JD, Hakala MT: Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res 40:4113-4122, 1980
3. Santi DV, McHenry CS, Sommer H: Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13:471-481, 1974
4. Heidelberger C, Griesbach L, Montag BJ: Studies on flourinated pyrimidines: II. Effects of transplanted tumors. Cancer Res 18:305, 1958
5. Vermund H, Gollin FF: Mechanisms of action of radiotherapy and chemotherapeutic adjuvants. A review. Cancer 21:58-76, 1968
6. Berry RJ: Effects of some metabolic inhibitors on x-ray dose-response curves for the survival of mammalian cells in vitro, and on early recovery between fractionated recovery between fractionated x-ray doses. Br J Radiol 39:458-463, 1966
7. Victti T, Eggerding F, Valeriote F: Combined effect of x radiation and 5-fluorouracil on survival of transplanted leukemic cells. J Natl Cancer Inst 47:865-870, 1971
8. Nakajima Y, Miyamoto T, Tanabe M: Enhancement of mammalian cell killing by 5-fluorouracil in combination with X-rays. Cancer Res 39:3763-3767, 1979
9. Bruso CE, Shewach DS, Lawrence TS: Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 19:1411, 1990
10. Heimburger DK, Shewach DS, Lawrence TS: The effect of fluorodeoxyuridine on sublethal damage repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 21:983-987, 1991
11. Miller EM, Kinsella TJ: Radiosensitization TJ: Radiosensitization by fluorodeoxyuridine: Effects of thymidylate synthase inhibition and cell synchronization. Cancer Res 52:1687-1694, 1992
12. Lawrence TS, Davis MA, Maybaum J: Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 29:519-523, 1994
13. Davis MA, Tang HY, Maybaum J, et al: Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. Int J Radiat Biol 67:509-517, 1995
14. Moertel CG, Childs DS Jr, Reitemeier RJ: Combined 5-fluorouracil and supervoltage radíation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865-867, 1969
15. Santelli G, Valeriote F: Schedule-dependent cytotoxicity of 5-fluorouracil in mice. J Natl Cancer Inst 76:159-164, 1986
16. Billingham RP: Conservative treatment of rectal cancer. Extending the indications. Cancer 70:1355-1363, 1992
17. Willett CG, Tepper JE, Kaufman DS: Adjuvant postoperative radiation therapy for rectal adenocarcinoma. Am J Clin Oncol 15:371-375, 1992
18. Bleday R, Steelc G Jr: Current protocols and outcomes of local therapy for rectal cancer. Surg Oncol Clin North Am 9:751-758 discussion 759-761, 2000
19. Brodsky JT, Richard GK, Cohen AM: Variables correlated with the risk of lymph node metastasis in early rectal cancer. Cancer 69:322-326, 1992
20. Willett CG, Tepper JE, Donnelly S: Patterns of failure following local excision and local excision and postoperative radiation therapy for invasive rectal adenocarcinoma. J Clin Oncol 7:1003-1008, 1989
21. Chakravarti A, Compton CC, Shellito PC: Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. Ann Surg 230:49-54, 1999
22. Wong CS, Stern H, Cummings BJ: Local excision and post-operative radiation therapy for rectal carcinoma. Int J Radiat Oncol Biol Phys 25:669-675, 1993
23. Fortunato L, Ahmad NR, Yeung RS: Long-term follow-up of local excision and radiation therapy for invasive rectal cancer. Dis Colon Rectum 38:1193-1199, 1995
24. Wagman R, Minsky BD, Cohen AM: Conservative management of rectal cancer with local excision and postoperative adjuvant therapy. Int J Radiat Oncol Biol Phys 44:841-846, 1999
25. Steele GD Jr, Herndon JE, Bleday R: Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol 6:433-441, 1999
26. Russell AH, Harris J, Rosenberg PJ: Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: Long-term results of radiation therapy oncology group protocol 89-02. Int J Radiat Oncol Biol Phys 46:313-322, 2000
27. Blair S, Ellenhorn JD: Transanal excision for low rectal cancers is curative in early-stage disease with favorable histology. Am Surg 66:817-820, 2000
28. Chari RS, Tyler DS, Anscher MS: Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 221:778-786, 1995
29. Minsky BD, Cohen AM, Kemeny N: Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 10:79-84, 1992
30. Minsky BD, Cohen AM, Enker WE: Sphincter preservation with preoperative radiation therapy and coloanal anastomosis. Int J Radiat Oncol Biol Phys 31:553-559, 1995
31. Mendenhall WM, Bland KI, Copeland EM 3rd: Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer? Ann Surg 215:696-705discussion 705-706, 1992
32. Myerson RJ, Michalski JM, King ML: Adjuvant radiation therapy for rectal carcinoma: predictors of outcome. Int J Radiat Oncol Biol Phys 32:41-50, 1995
33. Rich TA, Skibber JM, Ajani JA: Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 32:1025-1029, 1995
34. Roh MS, Petrelli N, Wicand S: Phase III randomized trial of preoperative versus postoperative multimodality therapy in patients with Carcinoma of the Rectum (NSABP R-03). Proc Am Soc Clin Oncol 2001 (abstr 490)
35. Allal AS, Bieri S, Pelloni A: Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: Feasibility, oncologic results and quality of life outcomes. Br J Cancer 82:1131-1137, 2000
36. Bosset JF, Magnin V, Maingon P: Preoperative radiochemotherapy in rectal cancer: Long-term results of a phase II trial. Int J Radiar Oncol Biol Phys 46:323-327, 2000
37. Gastrointestinal Tumor Study Group: Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 312:1465-1472, 1985
38. Krook JE, Moertel CG, Gunderson LL: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709-715, 1991
39. Fisher B, Wolmark N, Rockette H: Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01. J Natl Cancer Inst 80:21-29, 1988
40. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
41. Gastrointestinal Tumor Study Group: Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 10:549-557, 1992
42. O'Connell MJ, Martenson JA, Wicand HS: Improving adjuvant therapy for rectal cancer by combining protraeted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-1507, 1994
43. Tepper JE, O'Connell MJ, Petroni GR: Adjuvam post-operative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114. J Clin Oncol 15:2030-2039, 1997
44. Sauer R, Fietkau R, Wittekind C: Adjuvant versus neo-adjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of phase-III randomized trial (protocol CAO/ARO/AIO-94). Strahlenther Onkol 177:173-181, 2001
45. Miwa M, Ura M, Nishida M: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281, 1998
46. Schuller J, Cassidy J, Dumont E: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297, 2000
47. Ishikawa, T, Fukase Y, Yamamoto T: Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5′-deoxy-5-fluorocytidine (capecitabine). Biol Pharm Bull 21:713-717, 1998
48. Ishikawa T, Sekiguchi F, Fukase Y: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685-690, 1998
49. Rustum YM, Cao S: New drugs in therapy of colorectal cancer: Preclinical studies. Semin Oncol 26:612-620, 1999
50. Reigner B, Blesch K, Weidekamm E: Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85-104, 2001
51. Hoff PM, Ansari R, Batist G: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001
52. Van Cutsem E, Twelves C, Cassidy J: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001
53. Dunst J, Reese T, Sutter T: Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20:3983-3991, 2002
54. Kim JS, Cho MJ, Song KS: Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiar Oncol Biol Phys 54:403-408, 2002
55. Androulakis N, Kouroussis C, Kakolyris S: Phase I study of capecitabine combination with radiotherapy as adjuvant treatment for operable rectal cancer. Proc Am Soc Clin Oncol 2002 (abstr 2297)
56. Ngan S, Zalcberg J, Kell A: A Phase I Study of Capecitabine Combined with Radiotherapy for Locally Advanced Potentially Operable Rectal Cancer. Proc Am Soc Clin Oncol (Abstract # 591) 2001
57. Cunningham D, Pyrhonen S, James RD: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
58. Rougier P, Van Cutsem E, Bajetta E: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
59. Saltz LB, Cox JV, Blanke C: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
60. Douillard JY, Cunningham D, Roth AD: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
61. Garcia-Carbonero R, Supko JG: Current perspective, on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641-661, 2002
62. Rich TA, Kirichenko AV: Camptothecin radiation sensitization: Mechanisms, schedules, and timing. Oncology (Huntingt) 12:114-120, 1998
63. Chen AY, Choy H, Rothenberg ML: DNA topoisomerase I-targting drugs as radiation sensitizers. Oncology (Huntingt) 13:39-46, 1999
64. Tamura K, Takada M, Kawase I: Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 88:218-223, 1997
65. Wang DS, Ueno Y, Oyamada H: Enhancement of the antitumor efecct of gamma-ray irradiation in combination with camptothecin against human colorectal adenocarcinoma. Biol Pharm Bull 19:354-359, 1996
66. Hennequin C, Giocanti N, Balosso J: Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res 54:1720-1728, 1994.
67. Boscia RE, Korbut T, Holden SA: Interaction of topoisomerase I inhibitors with radiation in cis-diamminedi-chloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC tibrosarcoma in vivo. Int J Cancer 53:118-123, 1993
68. Minsky BD, O'Reilly E, Wong D: Low-dose irinotecan (CPT-11) plus pelvic irradiation as preoperative treatment of locally advanced rectal cancer (meeting abstract). Proc Am Soc Clin Oncol, 1999
69. Mitchell EP, Anne P, Fry R: Combined mordality therapy of locally advanced or recurrent adenocarcinoma of the rectum: Report of a phase I trial of chemtherapy (CT) with CPT-11, 5-FU and Concomitant Irratdiation (RT). Proc Am Soc Clin Oncol 2001 (abstr)
70. Mchta VK, Cho C, Ford JM: Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 55:132-7, 2003
71. Volter, V, Stupp R, Matter M: Preoperative hyperfractionated accelerated radiotherapy (HAER) and Concomitant CPT-11 in rectal Carcinoma. A Phase I/II Study. Proc Am Soc Clin Oncol 2001 (abstr)
72. de Gramont A, Figer A, Seymour M: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
73. Giacchetti S, Perpoint B, Zicklani R: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
74. Andre T, Louvet C, Raymond E: A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOL-FOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 9:1251-1253, 1998
75. Brienza S, Bensmaine MA, Soulic P: Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program. Ann Oncol 10:1311-1316, 1999
76. Maindrault-Goebel F, de Gramont A, Louvet C: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11:1477-83, 2000
77. Maindrault-Goebel F, de Gramont A, Louvet C: Highdose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37:1000-1005, 2001
78. Martoni A, Mini E, Pinto C [Oxaliplatin: Combinations with thymidylate synthetase inhibitors: two consecutive phase 11 studies]. Tumori 87:A25-26, 2001
79. Chau I, Webb A, Cunningham D: Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer 85:1258-64, 2001
80. Saris CP, van de Vaart Rietbroek RC: In vitro for mation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17:2763-2769, 1996
81. Woynarowski JM, Chapman WG, Napier C: Sequenceand region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54:770-777, 1998
82. Rixe O, Ortuzar W, Alvarez M: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865, 1996
83. Mamenta EL, Poma EE, Kaufmann WK: Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54:3500-3505, 1994
84. Schmidt W, Chaney SG: Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799-805, 1993
85. Graham MA, Lockwood GF, Greenslade D: Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205-1218, 2000
86. Massari C, Brienza S, Rotarski M: Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 45:157-164, 2000
87. Blackstock A, Hess S: Oxaliplatin: in vitro and in vivo evidence of its radiation sensitizing activity - pre-clinical observations relevant to ongoing clinical trials. Proc Am Assoc Cancer Res 41:53(abstr), 2000
88. Fischel J, Formento P, Dubreuil A: Radiotherapy (Rx) combined with the association oxaliplatin (OXA) - 5 fluorouracil-folinic acid (FUFA). Proc Am Assoc Cancer Res 42:386, 2001 (abstr)
89. Freyer G, Bossard N, Romestaing P: Addition of oxaliplatin to continuous fluorouracil, 1-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol 19:2433-2438, 2001
90. Gerard JP, Chapet O, Nemoz C: Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: The Lyon R0-04 Phase II Trial. J Clin Oncol 21:1119-1124, 2003
91. Aschele C, Friso ML, Pucciarelli S: A phase I-II study of weekly oxaliplatin (OXA), 5-fluorouracil (FU) continuous infusion (CI) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 2002 (abstr)
92. Sebag-Montefiore D, Glynne-Jones R, Falk S: Preoperative radiation and oxaliplatin in combination with 5-fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer. Proc Am Soc Clin Oncol 2002 (abstr)
93. Roca E, Carraro S, Cartelli. Radiochemotherapy with short daily infusion of low dose oxaliplatin, leucovorin and 5FU in T3-T4 unresectable rectal cancer. A phase II IATTGI Study. Proc Am Soc Clin Oncol 2002 (abstr)
94. Williams CS, Mann M, DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908-7916, 1999
95. Marnett LJ: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52:5575-5589, 1992
96. Oshima M, Dinchuk JE, Kargman SL: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809, 1996
97. Milas L, Kishi K, Hunter N: Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91:1501-1504, 1999
98. Kishi K, Petersen S, Petersen C: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60:1326-1331, 2000
99. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94:3336-3340, 1997
100. Masferrer JL, Koki A, Seibert K: COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci 889:84-86, 1999
101. Gorski DH, Mauceri HJ, Salloum RM: Potentiation of the antitumor cffect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58:5686-5689, 1998
102. Mauceri HJ, Hanna NN, Beckett MA: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-291, 1998
103. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18:4-25, 1997
104. Presta LG, Chen H, O'Connor SJ: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997
105. Gordon MS, Margolin K, Talpaz M: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
106. Margolin K, Gordon MS, Holmgren E: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19:851-856, 2001
107. Goldstein NS, Armin M: Epidermal growth factor immunohistochemical reactivity in patients with American Joint Committee on Cancel Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 92:1331-1346, 2001
108. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
109. Saltz L, Rubin M, Hochster H: Cetuximab (IMC-C225) plus irinotecan (PT-11) is active in CPT0 I-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:3a, 2001 (abstr)
110. Saltz L, Meropol NJ, Loehrer PJ: Single agent IMC-C225 (Eribitux has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 21:127a, 2002 (abstr)